Affimed(NASDAQ:AFMD) 
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-...
Website: http://www.affimed.com
Founded: 2000
Full Time Employees: 137
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2024-11-15
P
O 3.66
H 3.76
L 3.47
C 3.48
V 132,553
10EMA 3.48
20EMA 3.48
60EMA 3.48
120EMA 3.48
250EMA 3.48